Vivendy Therapeutics (Switzerland) developer of an enzyme replacement therapy for morbus morquio, a rare lysosomal storage disease closed a $15.5M Series A financing. Participants include BioMedInvest, LSP Life Sciences Partners and TVM Capital.

ProtAffin Biotechnologie (Austria) is focused on developing novel biotechnology therapeutic products for acute and chronic inflammatory diseases has closed a €4.0M Series A financing. Participants include The Entrepreneurs Fund BV, Aescap Venture Management and Z-Cube.

ProFibrix (Netherlands) a biotech company focused on fibrinogen-based products to stop surgical hemmoraging and initiate tissue repair, has closed a €8.5M Series A round. The deal was led by Index Ventures.

Affinium Pharmaceuticals (Canada) who is developing a new class of antibiotics targeting staph infections closed an $18M Series A financing. The deal was lead by Forward Ventures along with Oxford Bioscience , SV Life Sciences and Genesys Capital Partners.

Nitec Pharma (Switzerland) a drug company focused on the treatment of chronic inflammatory diseases with lead indications in Rheumatoid Arthritis and Polymylagia Rheumatica, raised $26M Series B round. The deal was led by NGN Capital other participants included Atlas Venture and Global Life Science Ventures.

Okairos (Switzerland) a biopharmaceutical company using adenovirus-based technology to focus on T-cell vaccines has closed a €7.2M Series A financing. The deal was led by Life Science Partners and Biomedinvest and was joined by the Novartis Venture Fund.

PainCeptor (Canada) a drug company focused on the treatment of chronic and acute pain raised a $20.8M Series B round. The deal was lead by Desjardins Venture Capital, CDP Capital, T2C2 Capital, Business Development Bank of Canada and Lothian Partners.

CoDa Therapeutics (New Zeland) -based drug company focused on Nexagon, a wound care and tissue repair therapeutic, raised a $20M Series A financing. The round was led by Domain Associates and GBS Venture Partners.

Cytochroma (Canada) a drug company focused on Psoriasis and chronic kidney disease raised Cnd$21M in Series C financing. Investors include VenGrowth Advanced Life Sciences Fund, Novo A/S and GeneChem Technologies Venture Fund.

Immatics Biotechnologies (Germany) developing immunotherapies for renal cell and colorectal carcinoma raised €40 in Series B funding. Participants included Dietmar Hopp, National Technology Enterprises Co., KfW, 3i Group and Wellington Partners.